Pacira Pharmaceuticals, Inc. (PCRX)

Company Description

Pacira Pharmaceuticals is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the US in April 2012. EXPAREL and two other products have utilized the PCRX proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.

 

COMPANY ADDRESS
5 Sylvan Way
Parsippany, NJ 07054
United States

COMPANY PHONE
973-254 3560

COMPANY WEBSITE



Get BioInvest's perspective on Pacira's CEO


Latest Company News

Pacira Pharmaceuticals, Inc. (PCRX) Receives New Coverage from Analysts at ... Sports Perspectives - 15 hours ago Pacira Pharmaceuticals logo Equities researchers at Canaccord Genuity assumed coverage on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a report released on Tuesday. The firm set a “buy” rating on the stock. PCRX has been the topic of a ... In Volatile Markets Do Analysts Think You Should Buy Pacira Pharmaceuticals ... - The De Soto Edge [...]
Tue, Feb 21, 2017 10:22:00 PM, Continue reading at the source
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Bearish Target At $89 Stock Observer - 15 hours ago Zacks Research has set ABR of 1.83 to Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). The average brokerage rating setup notes the stock ratings of radical research groups in the industry. [...]
Tue, Feb 21, 2017 10:14:00 PM, Continue reading at the source
Pacira Pharmaceuticals Announces Timing for 2016 Financial Results Webcast and ... Yahoo Finance - Feb 16, 2017 16, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (PCRX) today announced that financial results for the company's fourth quarter and year ended December 31, 2016 will be released before the market opens on Wednesday, March 1, 2017. The Pacira Pharmaceuticals Inc. (PCRX) Receives “Outperform” Rating from the ... - DailyQuint [...]
Thu, Feb 16, 2017 12:33:00 PM, Continue reading at the source
Pacira Pharmaceuticals, Inc. to Present at the 2017 RBC Capital Markets ... Yahoo Finance - Feb 15, 2017 15, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (PCRX) today announced that Pacira Pharmaceuticals management team is scheduled to participate in an analyst-led fireside chat at the 2017 RBC Capital Markets' Healthcare Conference at ... The Pacira Pharmaceuticals, Inc. (PCRX) Rating Increased to Buy at Zacks ... - DailyQuint [...]
Wed, Feb 15, 2017 3:21:00 PM, Continue reading at the source
DePuy Synthes Announces Exclusive Co-Promotional Agreement with Pacira ... PR Newswire (press release) - Jan 25, 2017 RAYNHAM, Mass., Jan. 25, 2017 /PRNewswire/ -- DePuy Synthes Companies today announced an exclusive agreement in the U.S. between DePuy Synthes Sales, Inc. and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) to co-promote EXPAREL®, ... Pacira Pharmaceuticals Announces Collaboration with DePuy Synthes to Support ... - Nasdaq Pacira Pharmaceuticals Inc. (PCRX) Moves Lower on Volume Spike for January 25 - Equities.com [...]
Wed, Jan 25, 2017 12:32:00 PM, Continue reading at the source
Why Pacira Pharmaceuticals, Inc. Shares Shot 17% Higher Today Motley Fool - Jan 6, 2017 Pacira Pharmaceuticals markets the surgical pain medicine Exparel, and growing demand for it helped the company produce $72.9 million in revenue during the fourth quarter, according to preliminary results. This Top Analyst Confident on Pacira Pharmaceuticals Inc Following 2016 Pre ... - Smarter Analyst [...]
Fri, Jan 06, 2017 11:26:00 PM, Continue reading at the source
Pacira Pharmaceuticals (PCRX) Q3 2016 Results - Earnings Call Transcript Seeking Alpha - Nov 2, 2016 Please be advised that this call is being recorded at the company's request and will be archived on the company's website for two weeks from today's date. At this time, I would like to introduce Jessica Cho of Pacira Pharmaceuticals. Ma'am, you may begin. [...]
Wed, Nov 02, 2016 7:46:00 PM, Continue reading at the source
Company Update (NASDAQ:PCRX): Pacira Pharmaceuticals Inc Announces Official ... Smarter Analyst - Sep 21, 2016 Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced new data regarding the benefit of EXPAREL®(bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to ... [...]
Wed, Sep 21, 2016 4:51:00 PM, Continue reading at the source
Why Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today Motley Fool - Aug 4, 2016 What: Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) are rallying 19.7% at 1:00 p.m. EDT after the company reported second-quarter financials that outpaced industry watchers' estimates. [...]
Thu, Aug 04, 2016 5:08:00 PM, Continue reading at the source
Pacira Pharmaceuticals Inc.'s Double-Digit Drop Explained Motley Fool - May 2, 2016 What: Shares of Pacira Pharmaceuticals (NASDAQ:PCRX), a specialty pharmaceutical company primarily focused on the development of medicines to help in the acute hospital care setting, dipped by as much as 10% during Monday's trading session after ... Company Update (NASDAQ:PCRX): Pacira Pharmaceuticals Inc Reports First Quarter ... - Smarter Analyst [...]
Mon, May 02, 2016 8:02:00 PM, Continue reading at the source